Human Molecular Genetics Advance Access published online on August 19, 2003
Human Molecular Genetics, doi:10.1093/hmg/ddg287
© 2003 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Molecular Genetics and Microbiology; Howard Hughes Medical Institute; Computational and Applied Genomics Program,
Institute for Genome Sciences and Policy, Duke University
* To whom correspondence should be addressed. E-mail: j.nevins{at}duke.edu.
Genomic data, particularly genome-scale measures of gene expression derived from DNA microarray studies, has the potential for adding enormous information to the analysis of biological phenotypes. Perhaps the most successful application of this data has been in the characterization of human cancers, including the ability to predict clinical outcomes. Nevertheless, most analyses have used gene expression profiles to define broad group distinctions, similar to the use of traditional clinical risk factors. As a result, there remains considerable heterogeneity within the broadly defined groups and thus predictions fall short of providing accurate predictions for individual patients. One strategy to resolve this heterogeneity is to make use of multiple gene expression patterns that are more powerful in defining individual characteristics and predicting outcomes than any single gene expression pattern. Statistical tree-based classification systems provide a framework for assessing multiple patterns, that we term metagenes, selecting those that are most capable of resolving the biological heterogeneity. Moreover, this framework provides a mechanism to combine multiple forms of data, both genomic and clinical, to most effectively characterize individual patients and achieve the goal of personalized predictions of clinical outcomes.
Article
Towards Integrated Clinico-Genomic Models for Personalized Medicine:
Combining Gene Expression Signatures and Clinical Factors in Breast Cancer Outcomes Prediction
2 Department of Molecular Genetics and Microbiology; Computational and Applied Genomics Program,
Institute for Genome Sciences and Policy, Duke University
3 Institute of Statistics and Decision Sciences, Duke University; Computational and Applied Genomics Program,
Institute for Genome Sciences and Policy, Duke University
4 Department of Medicine, Duke University Medical Center; Koo Foundation-Sun Yat Sen Cancer Center,Taipei, Taiwan; Computational and Applied Genomics Program,
Institute for Genome Sciences and Policy, Duke University
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. K Gruvberger-Saal, H. E Cunliffe, K. M Carr, and I. A Hedenfalk Microarrays in breast cancer research and clinical practice - the future lies ahead Endocr. Relat. Cancer, December 1, 2006; 13(4): 1017 - 1031. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Cheng, C.-F. Horng, M. West, E. Huang, J. Pittman, M.-H. Tsou, H. Dressman, C.-M. Chen, S. Y. Tsai, J. J. Jian, et al. Genomic Prediction of Locoregional Recurrence After Mastectomy in Breast Cancer J. Clin. Oncol., October 1, 2006; 24(28): 4594 - 4602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Potti, S. Mukherjee, R. Petersen, H. K. Dressman, A. Bild, J. Koontz, R. Kratzke, M. A. Watson, M. Kelley, G. S. Ginsburg, et al. A Genomic Strategy to Refine Prognosis in Early-Stage Non-Small-Cell Lung Cancer N. Engl. J. Med., August 10, 2006; 355(6): 570 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. West, G. S. Ginsburg, A. T. Huang, and J. R. Nevins Embracing the complexity of genomic data for personalized medicine. Genome Res., May 1, 2006; 16(5): 559 - 566. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Thrall Personalized Medicine Radiology, June 1, 2004; 231(3): 613 - 616. [Full Text] [PDF]
|
|